PE20141316A1 - Metodos para tratar la esclerosis multiple y preservar y/o aumentar el contenido de mielina - Google Patents
Metodos para tratar la esclerosis multiple y preservar y/o aumentar el contenido de mielinaInfo
- Publication number
- PE20141316A1 PE20141316A1 PE2013002710A PE2013002710A PE20141316A1 PE 20141316 A1 PE20141316 A1 PE 20141316A1 PE 2013002710 A PE2013002710 A PE 2013002710A PE 2013002710 A PE2013002710 A PE 2013002710A PE 20141316 A1 PE20141316 A1 PE 20141316A1
- Authority
- PE
- Peru
- Prior art keywords
- subject
- reduced
- multiple sclerosis
- preserve
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UN METODO PARA TRATAR UN SUJETO QUE TIENE ESCLEROSIS MULTIPLE, EL CUAL COMPRENDE ADMINISTRAR DE FORMA ORAL 480MG DE FUMARATO DE DIMETILO POR DIA DURANTE UN PERIODO DE TIEMPO SUFICIENTE PARA LOGRAR: i) FRECUENCIA REDUCIDA DE RECIDIVA EN EL SUJETO; ii) PROBABILIDAD REDUCIDA DE RECIDIVA EN EL SUJETO; iii) TASA DE RECIDIVA ANUALIZADA REDUCIDA EN EL SUJETO; iv) RIESGO REDUCIDO DE LA EVOLUCION DE DISCAPACIDAD EN EL SUJETO; v) NUMERO REDUCIDO DE LESIONES EN T2 RECIENTES O RECIENTEMENTE AUMENTADAS EN EL SUJETO; vi) NUMERO REDUCIDO DE LESIONES HIPOINTENSAS EN T1 NO REALZADAS RECIENTES EN EL SUJETO; ENTRE OTROS. TAMBIEN SE REFIERE A METODOS PARA PRESERVAR O AUMENTAR EL CONTENIDO DE MIELINA EN UN SUJETO QUE TIENE ESCLEROSIS MULTIPLE
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161490572P | 2011-05-26 | 2011-05-26 | |
US201261625624P | 2012-04-17 | 2012-04-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20141316A1 true PE20141316A1 (es) | 2014-10-01 |
Family
ID=47217796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2013002710A PE20141316A1 (es) | 2011-05-26 | 2012-05-25 | Metodos para tratar la esclerosis multiple y preservar y/o aumentar el contenido de mielina |
Country Status (18)
Country | Link |
---|---|
US (1) | US20140163100A1 (es) |
EP (1) | EP2713724A4 (es) |
JP (1) | JP2014515373A (es) |
KR (1) | KR20140036257A (es) |
CN (1) | CN103732062A (es) |
AU (1) | AU2012258558A1 (es) |
BR (1) | BR112013030169A2 (es) |
CA (1) | CA2836480A1 (es) |
CL (1) | CL2013003358A1 (es) |
CO (1) | CO6811862A2 (es) |
EA (1) | EA201391578A1 (es) |
EC (1) | ECSP13013117A (es) |
IL (1) | IL229448A0 (es) |
MX (1) | MX2013013781A (es) |
PE (1) | PE20141316A1 (es) |
SG (1) | SG195049A1 (es) |
WO (1) | WO2012162669A1 (es) |
ZA (1) | ZA201308681B (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0410805A (pt) | 2003-09-09 | 2006-06-27 | Fumapharm Ag | uso de derivados do ácido fumárico para tratamento da insuficiência cardìaca e asma |
DE14172398T1 (de) | 2004-10-08 | 2015-01-08 | Forward Pharma A/S | Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester |
DK2334378T3 (da) | 2008-08-19 | 2014-07-07 | Xenoport Inc | Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse |
HUE036085T2 (hu) | 2011-06-08 | 2018-06-28 | Biogen Ma Inc | Nagy tisztaságú és kristályos dimetil-fumarát elõállítására szolgáló eljárás |
AU2013305684B2 (en) | 2012-08-22 | 2016-11-24 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
US20140057918A1 (en) * | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof |
US10945984B2 (en) | 2012-08-22 | 2021-03-16 | Arbor Pharmaceuticals, Llc | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
US20140179779A1 (en) | 2012-12-21 | 2014-06-26 | Biogen Idec Ma Inc. | Deuterium Substituted Fumarate Derivatives |
US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
HUE040044T2 (hu) | 2013-03-14 | 2019-02-28 | Alkermes Pharma Ireland Ltd | Fumarátok prodrugjai, és azok alkalmazása különbözõ betegségek kezelésében |
WO2014160633A1 (en) | 2013-03-24 | 2014-10-02 | Xenoport, Inc. | Pharmaceutical compositions of dimethyl fumarate |
US9302977B2 (en) | 2013-06-07 | 2016-04-05 | Xenoport, Inc. | Method of making monomethyl fumarate |
WO2014205392A1 (en) | 2013-06-21 | 2014-12-24 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
TW201516020A (zh) | 2013-09-06 | 2015-05-01 | Xenoport Inc | (n,n-二乙基胺甲醯基)甲基(2e)丁-2-烯-1,4-二酸甲酯之晶形、合成方法及用途 |
CN103724198A (zh) * | 2013-11-28 | 2014-04-16 | 镇江圣安医药有限公司 | 富马酸二甲酯的新型衍生物及其应用 |
US9604922B2 (en) | 2014-02-24 | 2017-03-28 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
DK3110408T3 (en) | 2014-02-28 | 2019-04-29 | Banner Life Sciences Llc | ENTERY SOFT CAPS OF CONTROLLED RELEASE FUMAR TESTERS |
US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
EP3212626B1 (en) * | 2014-10-27 | 2018-11-07 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
MA40985A (fr) | 2014-11-17 | 2017-09-26 | Biogen Ma Inc | Méthodes de traitement de la sclérose en plaques |
MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
US11903918B2 (en) | 2020-01-10 | 2024-02-20 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19721099C2 (de) * | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
CA2478458A1 (en) * | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
CN101056624A (zh) * | 2004-10-08 | 2007-10-17 | Adi技术制药股份公司 | 包含富马酸酯的控释药物组合物 |
WO2007042034A1 (en) * | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
HRP20220902T3 (hr) * | 2007-02-08 | 2022-10-14 | Biogen Ma Inc. | Pripravci i njihova upotreba u liječenju multiple skleroze |
EP3135282A1 (en) * | 2007-02-08 | 2017-03-01 | Biogen MA Inc. | Neuroprotection in demyelinating diseases |
DK2334378T3 (da) * | 2008-08-19 | 2014-07-07 | Xenoport Inc | Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse |
EP3466420A1 (en) * | 2009-04-29 | 2019-04-10 | Biogen MA Inc. | Dimethyl fumarate for the treatment of friedreich ataxia |
-
2012
- 2012-05-25 EA EA201391578A patent/EA201391578A1/ru unknown
- 2012-05-25 AU AU2012258558A patent/AU2012258558A1/en not_active Abandoned
- 2012-05-25 US US14/119,373 patent/US20140163100A1/en not_active Abandoned
- 2012-05-25 SG SG2013085667A patent/SG195049A1/en unknown
- 2012-05-25 PE PE2013002710A patent/PE20141316A1/es not_active Application Discontinuation
- 2012-05-25 JP JP2014512168A patent/JP2014515373A/ja active Pending
- 2012-05-25 EP EP12789291.7A patent/EP2713724A4/en not_active Withdrawn
- 2012-05-25 CN CN201280036988.6A patent/CN103732062A/zh active Pending
- 2012-05-25 CA CA2836480A patent/CA2836480A1/en not_active Abandoned
- 2012-05-25 WO PCT/US2012/039721 patent/WO2012162669A1/en active Application Filing
- 2012-05-25 BR BR112013030169A patent/BR112013030169A2/pt not_active IP Right Cessation
- 2012-05-25 MX MX2013013781A patent/MX2013013781A/es unknown
- 2012-05-25 KR KR1020137034196A patent/KR20140036257A/ko not_active Application Discontinuation
-
2013
- 2013-11-14 IL IL229448A patent/IL229448A0/en unknown
- 2013-11-19 ZA ZA2013/08681A patent/ZA201308681B/en unknown
- 2013-11-22 CL CL2013003358A patent/CL2013003358A1/es unknown
- 2013-11-26 CO CO13277997A patent/CO6811862A2/es not_active Application Discontinuation
- 2013-12-26 EC ECSP13013117 patent/ECSP13013117A/es unknown
Also Published As
Publication number | Publication date |
---|---|
SG195049A1 (en) | 2013-12-30 |
CO6811862A2 (es) | 2013-12-16 |
CN103732062A (zh) | 2014-04-16 |
CA2836480A1 (en) | 2012-11-29 |
KR20140036257A (ko) | 2014-03-25 |
ECSP13013117A (es) | 2014-06-30 |
AU2012258558A1 (en) | 2013-05-02 |
ZA201308681B (en) | 2017-11-29 |
MX2013013781A (es) | 2014-01-08 |
BR112013030169A2 (pt) | 2016-08-09 |
EP2713724A1 (en) | 2014-04-09 |
EA201391578A1 (ru) | 2014-05-30 |
CL2013003358A1 (es) | 2014-08-01 |
JP2014515373A (ja) | 2014-06-30 |
US20140163100A1 (en) | 2014-06-12 |
EP2713724A4 (en) | 2015-03-11 |
IL229448A0 (en) | 2014-01-30 |
WO2012162669A1 (en) | 2012-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20141316A1 (es) | Metodos para tratar la esclerosis multiple y preservar y/o aumentar el contenido de mielina | |
IN2014CN04748A (es) | ||
CY1120385T1 (el) | Μεθοδος για την επεξεργασια της τεφρας, ιδιαιτερως της πτητικης τεφρας | |
MX2011007930A (es) | Conjugados de insulina cristalina. | |
MX2017003933A (es) | Metodos de tratamiento de la enfermedad hepatica. | |
TN2014000206A1 (en) | Antibody molecules having specificity for human ox40 | |
CL2011000513A1 (es) | Metodos para reducir o inhibir la angiogenesis en un sujeto que tiene una enfermedad o condicion ocular asociada con la angiogenesis que comprende la administracion de un antagonista de tetraspanina 12(tspan12) y/o un antagonista de norrina. | |
GB2510703A (en) | Travel headrest | |
NI201500150A (es) | TRATAMIENTO DE CÁNCER CON DIHIDROPIRAZINO-PIRAZINAS×Se proporcionan en la presente método | |
MX2013006056A (es) | Metodos para diagnosticar y tratar trastornos relacionados con la longitud del ojo. | |
MX364220B (es) | Metodos de tratamientos de fibrosis. | |
EA201591758A8 (ru) | Подкожное введение adamts13 | |
PE20150020A1 (es) | Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides | |
CR20140075A (es) | Métodos terapéuticos | |
DK201300530A (en) | Vaccine relating to Pancreas disease in fish | |
MX2014010940A (es) | El uso de antitrombina en el tratamiento de preeclampsia. | |
MX2013010050A (es) | Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus. | |
SG195170A1 (en) | Methods of treating or preventing rheumatic disease | |
MX2011012538A (es) | Terapia de combinacion para el tratamiento del mieloma multiple. | |
PH12015500708A1 (en) | Agent for enhancing immunity containing glutathione | |
UA103665C2 (ru) | Лечение фарингита, в том числе фарингомикоза и атрофического фарингита методом лазеротерапии | |
NZ629420A (en) | Sheep nematode vaccine | |
UA59766U (ru) | Способ медицинской реабилитации взрослых больных с посттравматическими стрессовыми расстройствами | |
UA106224C2 (en) | Crystalline insulin-conjugates | |
UA62210U (ru) | Способ лечения костно-мышечной патологии у детей с ювенильным ревматоидным артритом |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |